Novo Nordisk's Next Act: A US Listing, an Oral Pill Bet, and a Pipeline Racing a Patent Clock
Published on 09/24/2026 at 05:20 | Editorial boerse-global.de
Novo Nordisk is weighing a direct listing on the New York Stock Exchange, chief executive Mike Doustdar told the Financial Times, confirming the Danish drugmaker is open to the move even though no active process is underway. American investors currently gain exposure through depositary receipts, and a Wall Street quotation could widen the shareholder base while deepening liquidity in the home market of Novo's fiercest rivals.
The disclosure landed in the middle of another punishing stretch for the stock. Shares closed Wednesday at EUR 33.66, down 2.2%, extending a year-to-date decline of 24% that has left the equity well short of its former peaks.
A company that now earns most of its money in America
Behind the NYSE deliberations lies a structural shift. More than half of Novo Nordisk's total revenue is now generated in the United States, and its investor register has internationalized steadily over the past two decades. A direct US quotation would simplify access for American institutions — but it would also put management under a brighter spotlight as it works to rebuild market confidence after a string of disappointments.
That credibility gap was on full display at the company's capital markets day. Executives laid out targets stretching deep into the next decade, and shareholders responded coolly to the near-term growth outlook. The stock fell 8% immediately after the event, with the approaching loss of exclusivity on blockbuster semaglutide and intensifying competition both weighing on sentiment.
The question the market keeps asking
At the heart of the debate sits a single issue: will mid-decade revenue be enough to absorb the sales hole left when semaglutide's patent protection expires in the US and Europe in the early 2030s? Management has pledged to bring more than five potential blockbuster medicines to market by 2030, and is targeting risk-adjusted pipeline revenue above DKK 150 billion by 2035.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Those milestones are years away, and investors are growing skeptical about the intervening period. Absent firm confirmation that demand for existing GLP-1 therapies holds at record levels until the new generation arrives, market participants are increasingly pricing in transition risk. Guidance for 2026 to 2030 points to growth merely in line with the industry average — a sharp comedown for a company that spent years commanding double-digit expansion and the valuation premium that came with it.
CagriSema data offer a counterweight
Optimists point to fresh clinical evidence. On Monday, Novo reported encouraging results for CagriSema, its next-generation obesity candidate. In adults with type 2 diabetes, the drug achieved average weight loss of 12.4%, against 9.1% for Eli Lilly's tirzepatide, while matching its rival on HbA1c reduction. A separate trial in overweight or obese adults produced a 21.0% reduction in body weight, compared with just 2.0% on placebo.
The company also sees room to innovate on delivery. Doustdar predicts oral medicines could account for as much as half the global obesity market by 2030, and Novo is developing five distinct oral candidates. According to the company, its patented administration technology shields the formulation from generic competition until the mid-to-late 2030s. Competition from alternative treatment approaches is mounting all the same: injectable products have locked up enormous market share, and rivals are pushing into the gap with new mechanisms and high efficacy. Management is therefore accelerating tablet manufacturing capacity to meet expected demand.
CagriSema itself is slated to launch in early 2027, with the combination therapy positioned to reignite momentum in cardiometabolic disease.
Analysts trim their targets
Skepticism translated quickly into revised numbers. Deutsche Bank cut its price target to DKK 245 from DKK 265 while reiterating a sell rating. Jefferies, according to media reports, lowered its target to DKK 275 from DKK 285, keeping a hold recommendation.
The caution stems from concern that Novo could cede pricing power in its core diabetes and obesity franchise. Eli Lilly is pressing with its own offerings, and the looming semaglutide patent cliff threatens meaningful margin and price pressure. Should generic entrants arrive faster than the new candidates generate revenue, current margins would be exposed.
The levels that matter now
Technically, the picture hinges on the 52-week low of EUR 30.25. Holding above that floor leaves room for stabilization, a scenario in which investors reward clinical progress on CagriSema and the long-range pipeline plan. A sustained break below it, however, would risk widening the correction as the market discounts a deeper hit to future earnings.
The next tangible catalyst for repricing Novo's growth prospects is likely to be further progress on CagriSema's regulatory filings. For now, shareholders must weigh pipeline wins against the concrete transition risks that stretch to the end of the decade.
Ad
Novo Nordisk Stock: New Analysis - 24 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
